<DOC>
	<DOCNO>NCT00000800</DOCNO>
	<brief_summary>To determine whether methadone maintenance alters pharmacokinetics zidovudine ( AZT ) . To determine whether effect methadone disposition AZT time dependent whether metabolic interaction AZT methadone exist . Injection drug user represent increase proportion HIV-infected person . Since daily methadone maintenance major chemical treatment injection drug abuse , important determine impact methadone AZT absorption , distribution , elimination .</brief_summary>
	<brief_title>Methadone Effects Zidovudine ( ZDV , AZT ) Disposition</brief_title>
	<detailed_description>Injection drug user represent increase proportion HIV-infected person . Since daily methadone maintenance major chemical treatment injection drug abuse , important determine impact methadone AZT absorption , distribution , elimination . After 6 day inpatient detoxification clonidine , patient addict opiate randomize receive either oral intravenous AZT first dose , follow determination plasma urine pharmacokinetics . On second day AZT dosing , alternate form administration use first dose . On day , dos give orally . Patients begin methadone maintenance combination AZT 7 day inpatient treatment , pharmacokinetic sampling . After hospitalization 16 day total , patient continue AZT/methadone treatment outpatient basis , 2 month later readmitted inpatient 5 day pharmacokinetic sampling . Control patient addict opiate hospitalize 3 day study entry randomize AZT treatment pharmacokinetic sampling manner first group , although receive methadone treatment . Control patient readmitted 2 day 1 week AZT treatment 59 day AZT treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 count 100 500 cells/mm3 . No active opportunistic infection waste syndrome . Opiate addiction prior enrollment methadone treatment program ( methadone recipient ) . Admission General Clinical Research Center YaleNew Haven Hospital clonidine detoxification ( methadone recipient ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Inadequate IV access . Benzodiazepine abuse . Concurrent Medication : Excluded : Amiodarone . Anesthetics , general . Azithromycin . Barbiturates . Carbamazepine . Cimetidine . Ciprofloxacin . Clarithromycin . Dexamethasone . Disulfiram . Erythromycin . Fluoroquinolones . Fluoxetine . Gestodene . Hydrochlorothiazide . Hypoglycemics , oral . Isoniazid . Itraconazole . Ketoconazole . Levomepromazine . MAO inhibitor . Methoxsalen . Nafcillin . Narcotic analgesic . Naringenin . Norethindrone . Omeprazole . Pentazocine . Phenothiazines . Phenytoin . Quinidine . Ranitidine . Rifabutin . Rifampin . Sedative Hypnotics . Sulfaphenazole . Tranquilizers ( except discretion investigator protocol chair ) . Tricyclic antidepressant . Troleandomycin . Warfarin . Prior Medication : Excluded within 4 week prior study entry : Rifampin derivative . Phenytoin . Barbiturates . Cimetidine . Other drug know induce inhibit hepatic microsomal enzyme . Excluded within 14 day prior study entry : Any experimental drug . Drugs know nephrotoxic potential . Excluded within 72 hour prior study entry : Amiodarone . Anesthetics , general . Azithromycin . Carbamazepine . Ciprofloxacin . Clarithromycin . Dexamethasone . Disulfiram . Erythromycin . Fluoroquinolones . Fluoxetine . Gestodene . Hydrochlorothiazide . Hypoglycemics , oral . Isoniazid . Itraconazole . Ketoconazole . Levomepromazine . MAO inhibitor . Methoxsalen . Nafcillin . Narcotic analgesic . Naringenin . Norethindrone . Omeprazole . Pentazocine . Phenothiazines . Quinidine . Ranitidine . Rifabutin . Sedative Hypnotics . Sulfaphenazole . Tranquilizers ( except discretion investigator protocol chair ) . Tricyclic antidepressant . Troleandomycin . Warfarin . Continued active drug alcohol abuse dependence would decrease probability study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Methadone</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>